aTYR PHARMA INC Payments for (Proceeds from) Tenant Allowance
aTYR PHARMA INC (ATYR) reported Payments for (Proceeds from) Tenant Allowance of $5.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromTenantAllowance · last filed 2025-03-13
- aTYR PHARMA INC payments for (proceeds from) tenant allowance for the quarter ending 2024-12-31 was $0.00.
- aTYR PHARMA INC payments for (proceeds from) tenant allowance for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- aTYR PHARMA INC payments for (proceeds from) tenant allowance for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- aTYR PHARMA INC payments for (proceeds from) tenant allowance for the quarter ending 2024-03-31 was $5.30M, a 17.78% increase year-over-year.
- aTYR PHARMA INC payments for (proceeds from) tenant allowance for fiscal 2024 was $5.30M, a 6.00% increase from fiscal 2023.
- aTYR PHARMA INC payments for (proceeds from) tenant allowance for fiscal 2023 was $5.00M.
| Period end | Payments for (Proceeds from) Tenant Allowance 3 month | Payments for (Proceeds from) Tenant Allowance 6 month | Payments for (Proceeds from) Tenant Allowance 9 month | Payments for (Proceeds from) Tenant Allowance 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $5.30M 10-K · filed 2025-03-13 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $5.30M 10-Q · filed 2024-11-07 | $5.30M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $5.30M 10-Q · filed 2024-08-13 | $5.30M derived: sum of 3 quarters · filed 2024-08-13 | $5.50M derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | $5.30M 10-Q · filed 2024-05-02 | $5.30M derived: sum of 2 quarters · filed 2024-05-02 | $5.50M derived: sum of 3 quarters · filed 2024-05-02 | $5.80M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $200.00K derived: sum of 2 quarters · filed 2024-03-14 | $500.00K derived: sum of 3 quarters · filed 2024-03-14 | $5.00M 10-K · filed 2024-03-14 |
| 2023-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $500.00K derived: sum of 2 quarters · filed 2023-11-09 | $5.00M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $4.80M 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | $4.50M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |